Tricuspid Valve Regurgitation clinical trials at University of California Health

4 in progress, 1 open to eligible people

Showing trials for

  • Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial

    open to eligible people ages 18 years and up

    To establish the safety and effectiveness of the Edwards PASCAL Transcatheter Repair System in patients with symptomatic severe tricuspid regurgitation who have been determined to be at an intermediate or greater estimated risk of mortality with tricuspid valve surgery by the cardiac surgeon with concurrence by the local Heart Team

    at UC Irvine UCLA UCSF

  • TRISCEND II Pivotal Trial

    “Volunteer for research and contribute to discoveries that may improve health care for you, your family, and your community!”

    Sorry, in progress, not accepting new patients

    Pivotal trial to evaluate the safety and effectiveness of the Edwards EVOQUE tricuspid valve replacement system

    at UC Davis UCSF

  • TRIcvalve biCAVal Valve System for Severe Tricuspid Regurgitation (TRICAV-I)

    Sorry, not currently recruiting here

    The TricValve® Transcatheter Bicaval Valve System is a bicaval transcatheter tricuspid valve replacement system, which includes the TricValve® Transcatheter Bicaval Valve for superior vena cava (SVC) and the TricValve® Transcatheter Bicaval Valve for inferior vena cava (IVC). The TricValve® Transcatheter Bicaval Valves are pre-mounted into the TricValve® Delivery System which is used for percutaneous access and delivery of the TricValve® Transcatheter Bicaval Valve in the vena cava. The system is a single use, sterile device compatible with all the valve sizes. The prostheses are implanted percutaneously into the inferior and superior vena cava without disturbing the native tricuspid valve. The device is made of bovine pericardium leaflets sutured on a nitinol self-expanding stent system.

    at UCSF

  • TRILUMINATE Pivotal Trial

    Sorry, in progress, not accepting new patients

    The primary objective of this trial is to demonstrate the safety and effectiveness of the TriClip device in improving clinical outcomes in symptomatic patients with severe tricuspid regurgitation (TR), who are at intermediate or greater estimated risk for mortality or morbidity with tricuspid valve surgery. This randomized controlled trial will compare the investigational device (TriClip device) to Control (Medical Therapy).

    at UC Davis

Our lead scientists for Tricuspid Valve Regurgitation research studies include .

Last updated: